Literature DB >> 20635110

Methodological aspects of randomized controlled trials on cognitive interventions.

Alessandra Solari1.   

Abstract

The aims of this article were to assess the methodological challenges of randomized controlled trials (RCTs) on cognitive interventions for people with multiple sclerosis, and to discuss specific problems related to rehabilitation trials. A bibliographic search was carried out. Selected articles were examined using five methodological quality criteria related to description of the target population, method of allocation, masking of patient and examiner, the outcome measures and analysis. A total of 12 RCTs, published between 1996 and 2010, were found. Five RCTs were on drug therapy (two on disease-modifying therapies, one on donepezil and two on drugs for fatigue). Seven RCTs were on rehabilitation (six on PC-based retraining techniques). The quality of the studies was overall low, inadequate selection of the target population and limited study size being the most frequent limitations. No clear improvement was found in the most recent studies. Additional methodological problems specific to rehabilitation trials are difficulties in defining and reproducing the study intervention.

Entities:  

Mesh:

Year:  2010        PMID: 20635110     DOI: 10.1007/s10072-010-0375-5

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  14 in total

1.  The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus.

Authors:  A P Verhagen; H C de Vet; R A de Bie; A G Kessels; M Boers; L M Bouter; P G Knipschild
Journal:  J Clin Epidemiol       Date:  1998-12       Impact factor: 6.437

2.  Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration.

Authors:  Isabelle Boutron; David Moher; Douglas G Altman; Kenneth F Schulz; Philippe Ravaud
Journal:  Ann Intern Med       Date:  2008-02-19       Impact factor: 25.391

3.  Cognitive training in MS: effects and relation to brain atrophy.

Authors:  Helmut Hildebrandt; Michael Lanz; Horst K Hahn; Ebba Hoffmann; Björn Schwarze; Günther Schwendemann; Jürgen A Kraus
Journal:  Restor Neurol Neurosci       Date:  2007       Impact factor: 2.406

4.  Neuropsychologic status in multiple sclerosis after treatment with glatiramer.

Authors:  A Weinstein; S R Schwid; R B Schiffer; M P McDermott; D W Giang; A D Goodman; S I Schwid
Journal:  Arch Neurol       Date:  1999-03

5.  Treating learning impairments improves memory performance in multiple sclerosis: a randomized clinical trial.

Authors:  Nancy D Chiaravalloti; John DeLuca; Nancy B Moore; Joseph H Ricker
Journal:  Mult Scler       Date:  2005-02       Impact factor: 6.312

6.  Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group.

Authors:  J S Fischer; R L Priore; L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; D E Goodkin; C V Granger; J H Simon; J H Grafman; M D Lezak; K M O'Reilly Hovey; K K Perkins; D Barilla-Clark; M Schacter; D W Shucard; A L Davidson; K E Wende; D N Bourdette; M F Kooijmans-Coutinho
Journal:  Ann Neurol       Date:  2000-12       Impact factor: 10.422

7.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.

Authors:  Kenneth F Schulz; Douglas G Altman; David Moher
Journal:  BMJ       Date:  2010-03-23

8.  The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study.

Authors:  R C Smits; H H Emmen; F W Bertelsmann; B M Kulig; A C van Loenen; C H Polman
Journal:  Neurology       Date:  1994-09       Impact factor: 9.910

9.  Efficacy and specificity of intensive cognitive rehabilitation of attention and executive functions in multiple sclerosis.

Authors:  Flavia Mattioli; Mattioli Flavia; Chiara Stampatori; Deborah Zanotti; Giovanni Parrinello; Ruggero Capra
Journal:  J Neurol Sci       Date:  2009-10-13       Impact factor: 3.181

10.  The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis.

Authors:  M W Geisler; M Sliwinski; P K Coyle; D M Masur; C Doscher; L B Krupp
Journal:  Arch Neurol       Date:  1996-02
View more
  1 in total

Review 1.  Treatment of cognitive impairment in multiple sclerosis: position paper.

Authors:  Maria Pia Amato; Dawn Langdon; Xavier Montalban; Ralph H B Benedict; John DeLuca; Lauren B Krupp; Alan J Thompson; Giancarlo Comi
Journal:  J Neurol       Date:  2012-11-23       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.